Authors
Yasuhito Hagiwara, Yuuki Kuroda, Kenji Takai, Mayumi Ichikawa, Masayoshi Yamada, Yasuhiro Sugai, Masashi Koto
Published in
Journal of radiation research. Sep 28, 2026. Epub Sep 28, 2026.
Abstract
Concurrent chemoradiotherapy with thoracic radiotherapy of 45 Gy in 30 twice-daily fractions is the standard treatment for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal thoracic radiotherapy dose remains uncertain. This study aimed to evaluate the efficacy and safety of high-dose hyperfractionated radiotherapy for LS-SCLC. We retrospectively analyzed 38 patients with LS-SCLC who received high-dose hyperfractionated radiotherapy at multiple institutions in Yamagata Prefecture between 2008 and 2012. Radiotherapy was delivered at a total dose of 60 Gy in 50 twice-daily fractions of 1.2 Gy. The median follow-up was 31 months for the entire cohort and 107 months for surviving patients. The 3- and 5-year overall survival and progression-free survival were 46.1 and 26.2%, and 36.9 and 26.9%, respectively. The cumulative incidence of local recurrence in the high-dose region at 3- and 5-years was 13.5 and 18.9%, respectively. Grade 3 radiation pneumonitis occurred in three patients (7.9%). No grade 4 or higher radiation pneumonitis or grade 3 or higher esophagitis was observed. Grade 4 cytopenia occurred in six patients (16%). High-dose hyperfractionated radiotherapy may be a feasible dose-escalated option for patients with LS-SCLC, with acceptable toxicity. Published data on the long-term outcomes of this specific regimen are limited.
PMID:
42809411
Bibliographic data and abstract were imported from PubMed on 30 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0